Advanced Bladder Cancer Treatments in Knoxville, TN
Comprehensive care for non-muscle invasive and muscle-invasive bladder cancer. We offer modern intravesical therapies—including BCG, Anktiva (N-803), Adstiladrin, INLEXZO™ (TAR-200), and Zusduri—plus bladder-sparing strategies and coordinated surgical/oncology care close to home.
High-volume bladder cancer care
Patients across East Tennessee choose our fellowship-trained team for evaluation, treatment, and surveillance—without leaving Knoxville.
Modern intravesical therapies
Access to guideline-aligned options including BCG, Anktiva (N-803) with BCG, Adstiladrin, INLEXZO™ (TAR-200) for appropriate patients with BCG-unresponsive CIS, and Zusduri for select intermediate-risk non-muscle invasive disease.
Innovative options like Jelmyto
We provide Jelmyto, a mitomycin-containing reverse thermal gel, for patients with low-grade upper tract urothelial carcinoma, allowing a kidney-sparing approach when appropriate.
Conditions We Treat
- Non-muscle invasive bladder cancer (Ta, T1, CIS)
- Muscle-invasive bladder cancer
- Upper tract urothelial carcinoma (kidney/ureter)
- Recurrent or BCG-unresponsive disease
Our Diagnostic Approach
- Office evaluation with cystoscopy and imaging as appropriate
- TURBT for tissue diagnosis and staging
- Risk stratification and personalized surveillance plans
Personalized Treatment Pathways
| Setting | Goal | Examples |
|---|---|---|
| Non-Muscle Invasive | Clear visible disease and reduce recurrence/progression | TURBT → intravesical therapy such as BCG; for appropriate patients, Anktiva (N-803) with BCG, Zusduri, Adstiladrin, or INLEXZO™ (TAR-200) (sustained-release intravesical gemcitabine delivery system for appropriate patients with BCG-unresponsive CIS); alternative intravesical chemotherapy as indicated. |
| Muscle-Invasive | Definitive local control and survival | Cystectomy consultation and coordination; bladder-sparing strategies when appropriate in collaboration with radiation/medical oncology. |
| Upper Tract Urothelial Cancer | Organ preservation when feasible | Endoscopic and segmental approaches for select cases; multidisciplinary review. |
| Survivorship | Early detection of recurrence and support | Structured surveillance with cystoscopy, urine studies, and imaging as indicated; symptom management and nurse navigation. |
Treatment selection depends on tumor stage, grade, prior therapies, pathology, and overall health. We’ll discuss benefits, risks, and follow-up for each option.
New Diagnosis or Recurrence?
Contact us for a timely consult. We’ll review your records, discuss options, and plan next steps.
Related Services
We coordinate closely with UT Medical Center’s multidisciplinary team for radiation and medical oncology when needed.
Frequently Asked Questions
What is Adstiladrin?
An FDA-approved intravesical gene therapy (nadofaragene firadenovec) for select BCG-unresponsive non-muscle invasive bladder cancer. We’ll review whether it fits your situation.
What is Anktiva (N-803)?
A modern immunotherapy used with BCG in appropriate patients with certain forms of NMIBC. Your urologist will discuss candidacy and follow-up needs.
What is INLEXZO™ (TAR-200)?
INLEXZO is an FDA-approved intravesical drug-delivery system for certain patients with BCG-unresponsive non-muscle invasive bladder cancer with CIS. It is placed through a catheter and remains in the bladder for about three weeks per cycle, steadily releasing gemcitabine as a bladder-sparing, sustained-release option compared with traditional short “dwell time” instillations.
Contact University Urology
University of Tennessee Medical Center
1928 Alcoa Highway, Building B, Suite 222 • Knoxville, TN 37920
Hours: Mon–Fri 8:00–4:30 • Satellite office hours vary by provider and location.
Learn more of about Bladder Cancer Basics with Dr. Bienvenu